Following the FDA’s recent decision to tighten regulations for clinical laboratories, RTW Investments, LP Partner and Portfolio Manager Naveen Yalamanchi recently spoke with the The Wall Street Journal Journal’s Brian Gormley to discuss the impact this will have on lab-testing startups and the venture capital firms that invest in them. Read the full article here (subscription required): https://lnkd.in/epi7vtGm #Biotech #LDTs #Investing #Regulation
RTW Investments, LP
Investment Management
New York, NY 5,345 followers
Innovation is the Best Medicine
About us
RTW is a life sciences investment and innovation firm. Headquartered in New York with offices in London and Shanghai, we invest across the full lifecycle of companies including company creation, early stage venture capital, alternative financing, and public company investments.
- Website
-
http://www.rtwfunds.com
External link for RTW Investments, LP
- Industry
- Investment Management
- Company size
- 51-200 employees
- Headquarters
- New York, NY
- Type
- Privately Held
Locations
-
Primary
Get directions
40 10th Avenue
Floor 7
New York, NY 10014, US
Employees at RTW Investments, LP
Updates
-
Our Chief Business Officer Stephanie A. Sirota recently sat down with Labiotech.eu’s Beyond Biotech Podcast to discuss the evolution of RTW’s research-driven approach over the last 15 years, the incredible innovation taking place in medicine, and why the firm is excited about the outlook of the biotech market in 2024 and beyond. You can listen to the full episode here, as well as on most podcast platforms: https://lnkd.in/eAGaEgPY #lifesciences #biotech #investing #markets #podcast
-
-
Insightful piece by Kyle LaHucik in Endpoints News about the return of private “mega-rounds” in biotech, or venture financings totaling more than $100 million. Features some great commentary from Cormorant Asset Management, LP, Leerink Partners, Novo Holdings, and our own managing partner and CIO, Roderick Wong. https://lnkd.in/e5wq3tzM #biotech #financing #venturecapital
The megaround rebound: Private biotechs rack up $100M+ financings
https://endpts.com
-
Newly approved treatments for obesity have many asking what’s next. Our managing partner and CIO Roderick Wong recently sat down with Cambridge Associates for their #UnseenUpside #podcast to share his thoughts, what he’s looking at in the next generation of #obesity treatments, and the broader health implications of tackling obesity. The episode features additional voices including Structure Therapeutics CEO Raymond Stevens. Listen here: https://ow.ly/egBa50QMj0C #lifesciences #investing #biotech
-
-
Congrats to the Rocket Pharmaceuticals team! Well-deserved recognition.
Humbled to be named a Fast Company Most Innovative Company of 2024, as we seek #GeneTherapy cures for patients with rare and devastating diseases across our world-class pipeline of six disclosed programs. Learn more: https://lnkd.in/ekxmwYzp. #FCMostInnovative
-
-
ICYMI: Last week Amber Tong of Endpoints News published an insightful piece on biotech in China in which our own Roderick Wong and Peter Fong provided a counterpoint to the “in-licensing model is dead” narrative and bring some optimism for underserved patients in China. https://lnkd.in/edetXcYF
Startups raised millions to in-license drugs to China. Then the model fell apart
https://endpts.com
-
RTW Investments, LP reposted this
RTW Partner and Chief Business Officer, Stephanie A. Sirota shares her perspective on #womenshistorymonth and progress in our industry. #womeninscience #biotech #finance
-
-
RTW Partner and Chief Business Officer, Stephanie A. Sirota shares her perspective on #womenshistorymonth and progress in our industry. #womeninscience #biotech #finance
-
-
In honor of Rare Disease Day, RTW Charitable Foundation launched its new podcast today: The Zebras Herd. Give it a listen and help spread awareness. #rarediseaseday #rarediseaseawareness #raredisease #ultrarare #podcast
Today is Rare Disease Day! To recognize it, we are launching our new podcast The Zebras Herd. We will be featuring conversations about science, advocacy, policy, and all things related to ultrarare disease. In the first episode we're joined by Dr. Steven Gray, Associate Professor at the University of Texas Southwestern Medical Center. Dr. Gray is a world leader in gene therapy for ultrarare diseases. During this wide-ranging conversation, we spoke about the keys to his success, how he engages with disease foundations, how he trains people, and the future of the field. Click below to listen: https://lnkd.in/enXezqCq #rarediseaseday #rarediseaseawareness #raredisease #ultrarare #podcast
-